Technology, Politics, Mind. Since 2014.
Silicon Canals Editorial Team
Editorial Team

Silicon Canals Editorial Team

Editorial Team

The Silicon Canals Editorial Team produces content across our three editorial pillars: technology and business, power and investigations, and human systems. We chronicle the systems that shape our lives, from the global infrastructure of technology to the internal infrastructure of the human mind. Articles reflect our team's collective editorial process, sourcing, drafting, fact-checking, editing, and review, rather than a single journalist's writing. Silicon Canals takes editorial responsibility for content under this byline. For more on how we work, see our editorial policy.

External profile →

Health Tech

Roughly one in eight American adults is now on a GLP-1 drug like Ozempic — a class that grew out of a hormone one Bronx doctor found in Gila monster venom, then patented himself after his own employer passed on it

Roughly one in eight American adults is now taking a GLP-1 drug like Ozempic, Wegovy or Zepbound. The class traces back to a hormone isolated from Gila monster venom by a Bronx doctor who paid a dollar to file the patent himself after his employer passed on it.

Business

There’s a German idea that explains why the most globally dominant companies in their field are ones you’ve never heard of — quiet, family-run, mid-sized firms that would rather own an obscure world market than ever be famous

If you own a dog, there is a reasonable chance its retractable lead was made by a company called Flexi, based in a town in northern Germany, which by its own account and most industry estimates holds around 70 percent of the world market for exactly that product and does nothing else.